ArticleBritish journal of clinical pharmacology2025
The prevalence of polypharmacy increases with age among patients with inflammatory bowel disease: A nationwide cohort study.
Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The prevalence of polypharmacy increases with age among patients with inflammatory bowel disease: A nationwide cohort study.British journal of clinical pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsPolypharmacy is common in adult patients with inflammatory bowel disease (IBD). This study aims to quantify medication prescriptions and estimate the risk of polypharmacy over time in older adults with IBD.
methodsIn a nationwide cohort of adult incident IBD patients from 1 April 1996, to 31 December 2019, we examined medication prescriptions across calendar years among young adults (18-39 years), adults (40-59 years), older adults (60-79 years) and oldest adults (≥80 years). The prescriptions (ATC:level-3) were grouped into 0, 1-4, 5-9 (moderate polypharmacy) and ≥10 (excessive polypharmacy) and described 1 year pre-IBD diagnosis, and 1, 2 and 3 years post-IBD diagnosis. We estimated the risk of polypharmacy (moderate and excessive) 1-year post-IBD diagnosis in patients (≥60 years) using regression models, comparing recent to early years.
resultsWe included 21 255 young adults, 13 432 adults, 8271 older adults and 933 oldest adults. The prevalence of moderate polypharmacy 1-year post-IBD diagnosis for young adults, adults, older adults and the oldest adults was 15.1, 23.2, 38.1 and 49.4%, respectively. The corresponding proportions for excessive polypharmacy were 1.5, 5.4, 16.6 and 23.4%, respectively. The adjusted odds ratio for polypharmacy among patients ages ≥60 years in 2020 vs. 1997 was 1.02 (95% confidence interval: 0.71-1.47).
conclusionThe prevalence of polypharmacy was high and increased with increasing age. In all age groups, the year-by-year level of polypharmacy was stable. For patients aged ≥60 years, there were no signs of a decreasing trend. Polypharmacy seems to be an existing problem and awareness of ensuring appropriate prescribing is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.